NFE2L2 and lung carcinoma: Dysregulation of KEAP/NRF2 pathway due to loss of function mutations in the KEAP1 gene as well as gain-of-function mutations in NRF2 and epigenetic changes leads to drug- and radio-resistance in lung cancer 7.